baber/WOPTO huggingface dataset:
Patent NZ-578785-A (NZ)
Title: Manufacture of paper or paperboard
Inventor: REINICKE HOLGER
IPC: D21H17/42
Filed: 2008-01-22
Abstract: Disclosed is a process of making paper or paperboard with improved ash retention relative to total retention comprising the steps of providing a thick stock cellulosic suspension that contains filler, diluting the thick stock suspension to form a thin stock suspension, in which the filler is present in the thin stock suspension in an amount of at least 10% by weight based on dry weight of thin stock suspension flocculating the thick stock suspension and/or the thin stock using a polymeric retention/drainage system, draining the thin stock suspension on a screen to form a sheet and then drying the sheet, in which the polymeric retention/drainage system comprises, i) a water-soluble branched anionic polymer and ii) a water-soluble cationic or amphoteric polymer, wherein the anionic polymer is present in the thick stock or thin stock suspension prior to the addition of the cationic or amphoteric polymer.
Patent NZ-588499-A (NZ)
Title: Controlled-release particles with core comprising a weakly basic drug and a controlled-release coating
Inventor: VENKATESH GOPI
IPC: A61K9/22
Filed: 2009-04-15
Abstract: ABSTRACT: 588499 The present disclosure is directed to pharmaceutical compositions, and methods of making such compositions, comprising microparticles containing a weakly basic drug core, a layer of alkaline buffer, and a controlled-release coating. Particularly disclosed is a pharmaceutical composition comprising a plurality of controlled-release particles, wherein at least one population of said particles comprises:(a) a core comprising a weakly basic drug, or a pharmaceutically 5 acceptable salt, solvate, and/or ester thereof; (b) an alkaline-buffer layer disposed over the core, comprising an alkaline buffer; and(c) a controlled-release coating disposed over the alkaline-buffer layer, wherein the controlled-release coating comprises a water-insoluble polymer selected from the group consisting of ethylcellulose, cellulose acetate, cellulose acetate butyrate, polyvinyl acetate, neutral methacrylic acid-methylmethacrylate copolymers, and mixtures thereof and said enteric polymer is selected from the group consisting of hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, pH-sensitive methacrylic acid methylmethacrylate copolymers, shellac, and mixtures thereof. The disclosure is also directed to pharmaceutical dosage forms, including orally disintegrating tablets, conventional tablets, and capsules, and methods for their preparation.
Patent NZ-589718-A (NZ)
Title: A transdermal drug delivery device
Inventor: EASTERBROOK TIMOTHY J
IPC: A61K31/46
Filed: 2009-06-02
Abstract: Disclosed is transdermal drug delivery device in the form of a matrix system comprising a backing layer, a drug containing adhesive layer and a release liner, in which the drug containing adhesive layer comprises a neutral polyacrylate without functionality having a uniform dispersion of a parasympathomimetic and a parasympatholytic therein. A method of manufacturing the transdermal device is also disclosed. The device is used to treat poisoning by highly toxic organophosphates.
Patent NZ-591740-A (NZ)
Title: Horizontal shaft impact crusher with crushing curtains which are moveable relative to an impeller
Inventor: DALLIMORE ROWAN
IPC: B02C13/09
Filed: 2009-11-19
Abstract: Disclosed is a horizontal shaft impact crusher (1) for crushing material by impacting the material with beater type elements and further by impacting the material against breaker plates referred to as curtains. The crusher comprises a housing (2), an impeller (4), and a first (28) and a second (30) curtain against which material accelerated by the impeller may be crushed. The second curtain is located downstream of the first curtain. The housing is provided with a first (20) and a second pivot point (corresponding to shaft 36) for mounting a first end (34) of the first curtain in two different positions relative to the impeller, a first adjustment device (42) for mounting a second end (40) of the first curtain (28). The housing further has a third (24) and a fourth pivot point (corresponding to shaft 54) for mounting a first end (52) of the second curtain in two different positions relative to the impeller (4), and a second adjustment device (62) for mounting a second end (58) of said second curtain. The adjustable curtain positions give the crusher the ability to crush material with a wider range of sizes.
Patent NZ-593155-A (NZ)
Title: High affinity human antibodies to human proprotein convertase subtilisin/kexin type 9
Inventor: SLEEMAN MARK W
IPC: A61K47/64
Filed: 2009-12-15
Abstract: Disclosed is a human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.
Patent NZ-593880-A (NZ)
Title: Pressure-sensitive adhesive tape package
Inventor: MIYACHI ISAO
IPC: A61F13/02
Filed: 2009-12-14
Abstract: 593880 A pressure-sensitive adhesive tape package (10) which can contribute to resource saving while attaining easy application of the pressure-sensitive adhesive tape (14). The package (10) accommodates an adhesive tape (14) having a support (18) and an adhesive agent layer (12) provided on one surface of the support (18). The package (10) comprises a release sheet (16) releasably attached to the adhesive agent layer (12), with the release sheet (16) bent into a first portion (20) and a second portion (22) along a predetermined first bending line. The adhesive tape (14) is bent into a first portion (26) and a second portion (28) along a predetermined second bending line such that the adhesive agent layer (12) faces outwardly. The bent adhesive tape (14) is sealed inside of the bent release sheet (16). The first portion (26) of the adhesive tape (14) is larger than the second portion (28) of the adhesive tape (14), and the first portion (26) has an extending portion that extends from the second portion (28). Temporary attaching means (24) are provided in at least a part of a portion of the release sheet (16) on the second portion side of the adhesive tape (14), the portion of the release sheet facing the extending portion of the adhesive tape (14).
Patent NZ-593905-A (NZ)
Title: Il-1 binding proteins
Inventor: WU CHENGBIN
IPC: C07K16/24
Filed: 2010-01-29
Abstract: 593905 Provided are humanized IL-1 antibodies, which can be used to treat various immunological diseases, including arthritis, asthma, arthropathy, various infections and mental disorders, among others. Further provided are corresponding peptide encoding DNA sequences, vectors containing them and host cells comprising the vectors.
Patent NZ-594146-A (NZ)
Title: Process for preparing chocolate crumb
Inventor: GODFREY GRAHAM
IPC: A23G1/56
Filed: 2010-02-03
Abstract: Disclosed is a process for preparing chocolate crumb comprising: a) providing a milk and sugar mixture or mixing together, milk and sugar so as to form a mixture; b) evaporating liquid from the mixture so as to form sweetened condensed milk; c) adding and mixing cocoa mass/liquor to the sweetened condensed milk; d) subjecting the sweetened condensed milk and cocoa mass/liquor mixture to conditions effective to bring about sugar crystallisation in the mixture; e) drying the mixture so as to form chocolate crumb; and f) seeding the mixture with sugar during step (c).
Patent NZ-594338-A (NZ)
Title: Apparatus, systems and methods for achieving intravascular, thermally-induced renal neuromodulation
Inventor: WU ANDREW
IPC: A61M25/00
Filed: 2009-12-22
Abstract: 594338 Disclosed is a catheter apparatus for intravascular thermal neuromodular stimulation. The catheter apparatus comprises an elongated shaft (16), having a proximal end region (18) and a distal end region (20), and a handle (200) coupled to the proximal end region. The distal end region includes a first flexure zone (32) and a second flexure zone (34) adjacent to and extending distally beyond the first flexure zone. A thermal element (24), comprising a single distal tip electrode having an atraumatic tip, is carried by and extends distally beyond the second flexure zone and is configured to apply treatment to a tissue region adjacent to the tissue surface. A flexure control element (see 40, figure 15C) is coupled to the first flexure zone and is configured to apply a first force to the first flexure zone to move the first flexure zone of the distal region of the elongated shaft in a radial direction away from the axis. A flexure controller (260) is carried by the handle and is coupled to the flexure control element which is configured to cause the flexure control element to apply the first force to move the first flexure zone. A connector is carried by the handle and configured to connect the thermal element to a thermal energy source. A flexible structure (44) within the second flexure zone is coupled to the thermal element and is configured to allow passive flexure in any plane about the axis in response to a second force applied to the thermal element via contact with a tissue surface. This passive flexure is advantageous in accommodating flexure sufficient for the distal end to advance through an artery without straightening, to avoid damaging the artery walls, and also orients a side of the thermal element against an artery wall to provide additional stability.
Patent NZ-595185-A (NZ)
Title: Triggered release of a compound or composition into solution using porus particles
Inventor: BARBE CHRISTOPHE JEAN ALEXANDRE
IPC: A01N29/06
Filed: 2009-12-22
Abstract: A method is described for delivering a species to a liquid, whereby porous particles are exposed to a condition such that the species is rapidly released into the liquid. Each of the porous particles comprises an agglomeration of primary particles so that outer surfaces of said primary particles define pores of said porous particles. The primary particles comprise silica and the species is disposed in the pores of the porous particles. The porous particles may be dispersed in a diluent. The diluent may be the liquid to which the species is to be delivered. It may be some other diluent. It may be miscible with the liquid to which the species is to be delivered. The exposing may be in the presence of the liquid. In many embodiments either the porous particles are provided in the liquid or the step of exposing comprises exposing the porous particles to the liquid The species may be a biological species. It may be, or may comprise, a protein, a peptide, an oligopeptide, a synthetic polypeptide, a saccharide, a polysaccharide, a glycoprotein, an enzyme, DNA, RNA, a DNA fragment or a mixture of any two or more of these. It may be, or may comprise, some other macromolecular species. It may be, or may comprise, a polymer, e.g. a polymeric dye. It may be, or may comprise, a particulate species. It may be, or may comprise, cells or viral particles. The species may be any suitable species that is sufficiently large (e.g. has sufficiently large diameter) to remain encapsulated by the porous particles and not be released to a substantial degree until the porous particles are exposed to the condition leading to rapid release of said species. The condition may be such that the silica of the primary particles at least partially dissolves or hydrolyses so as to rapidly release the species. It may be such that bridges joining the primary particles at least partially dissolve or hydrolyse. Said dissolution or hydrolysis may result in at least partial disintegration or de-aggregation of the porous particles. It may result in rapid release of the species. The dissolution or hydrolysis may represent an "unzipping" or de-esterification of Si-O-Si linkages which form said bridges.
Patent NZ-598758-A (NZ)
Title: N-4 (-((3-(2-amino-4 pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
Inventor: KENDALL RICHARD
IPC: A61K31/502
Filed: 2010-09-09
Abstract: 598758 Disclosed herein is the use of N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine or a pharmaceutically acceptable salt thereof, to treat cancers, including solid tumors, which have become resistant to treatment with chemotherapeutic agents, including anti-mitotic agents such as taxanes, and/or other anti-cancer agents, including aurora kinase inhibiting agents. The invention also includes the use in the treatment of cancers refractory to such treatments by administering a pharmaceutical composition, comprising the compound to a cancer subject.
Patent NZ-599783-A (NZ)
Title: Composition and use for alpha-1 proteinase inhibitor
Inventor: GUO JIANXIN
IPC: A61K9/08
Filed: 2010-11-02
Abstract: Disclosed are compositions comprising API and at least one amino acid, in particular a liquid API formulation comprising amino acids, and methods and kits related thereto. These amino acids when incorporated into the API composition afford stability to the API formulation.
Patent NZ-601369-A (NZ)
Title: Phase current measurement module for an electricity meter, provided with a current cutoff function
Inventor: GUILLON JEAN-LOUIS
IPC: G01R11/04
Filed: 2010-12-03
Abstract: 601396 Disclosed is a phase current measurement module adapted to be used in an electricity meter. The module includes at least one current measurement sensor (C1) comprising a metal conductor (1) intended to be passed through by the phase current to be measured between an input terminal (E) and an output terminal (S) of the meter corresponding to the phase. A phase current interrupter means (2) is connected in series between the metal conductor (1) of the sensor (C1) and the output terminal (S) of the meter. Also included is a bistable electromechanical control element with a winding (20) which enclose two metal elements (21, 22) forming a stator, a rotor (23) mounted so as to be movable in rotation about an axis between the two metal elements (21, 22) forming the stator. The rotor including a magnetic mass moved in rotation by a magnetic field generated by the stator when a pulse of control current passes through the winding (20), and an actuator (25) rotatably connected to the axis of the rotor. The actuator (25) is capable of being displaced between two extreme angular positions corresponding respectively to a stable open position and a stable closed position of the phase current interrupter means (2). A set of two parallel resilient metal strips (3, 4) is fixed symmetrically on both sides of a first flat portion (10) connected electrically to the metal conductor (1). Each free end of the two strips (3, 4) bears a metal contact. Each metal contact is intended, under the action of the control element, for toggling between the open position, and the closed position of the interrupter means (2) to come simultaneously into contact with or to move apart simultaneously from two contact pads disposed symmetrically on both sides of a second flat portion (5). The second flat portion (5) is connected electrically to the output terminal (S) of the meter and disposed in the same plane as the first flat portion (10). The axis of the rotor (23) extends orthogonally with respect to the direction of the two resilient metal strips (3, 4). The actuator (25) is arranged between the two resilient metal strips (3, 4) in such a way as to cause, depending upon the angular position occupied by the actuator (25), the free ends of the resilient metal strips (3, 4) to move apart from one another or to move closer together and consequently to cause the interrupter means to toggle respectively into the open position or the closed position.
Patent NZ-609887-A (NZ)
Title: Antibody against human prostaglandin e2 receptor ep4
Inventor: TAKAYAMA KIYOSHI
IPC: C12P21/08
Filed: 2011-09-28
Abstract: Disclosed is an isolated monoclonal antibody or an antigen-binding fragment thereof, which specifically binds to the extracellular domain of EP4 expressed on the cell surface of mammalian cells, and inhibits the cellular function of EP4 to increase the intracellular cAMP level and does not bind to EP1, EP2 or EP3. Also disclosed is the use of the monoclonal antibody or an antigen-binding fragment thereof for the treatment of EP4-related immunological diseases, a tumor or pain.
Patent NZ-612482-A (NZ)
Title: Spirally wound microbial fuel cell
Inventor: SHECHTER RONEN ITZHAK
IPC: H01M8/16
Filed: 2010-12-14
Abstract: 612482 A bacterial fuel cell (100) with at least one anode (102) and at least two cathodes (104) in liquid communication with a liquid to be treated (106). The anode (102) is separated from the cathodes (104) by a first and second electrically insulating spacers (114). The anode (102) and the cathodes (104) are electrically connected across an external load (116). The anode (102) and cathodes (104) are wound together generally in a spiral configuration (108) together with at least a third electrically insulating spacer (110).
Patent NZ-613544-A (NZ)
Title: Bifidobacterium bifidum strains for application in gastrointestinal diseases
Inventor: GUGLIELMETTI SIMONE
IPC: A61K35/745
Filed: 2012-01-27
Abstract: Disclosed is the use of a probiotic formulation comprising a strain of Bifidobacterium bifidum MIMBb75, deposited under deposit No. DSM 24514, in the preparation of a pharmaceutical composition for the treatment of irritable bowel syndrome.
Patent NZ-615631-A (NZ)
Title: Tamper evident device
Inventor: BORTZ GARY
IPC: A44B19/26
Filed: 2007-07-04
Abstract: A security device 10 for a container closeable by a slide fastener having a slider 16, comprises a lower part 12 adapted for attachment to the container, means 54 for attaching the security device 10 to the slider 16, an upper part 20 for retaining the attaching means 54, and means 28 to limit access to the attaching means 54. The security device 10 includes a first fastening means for fixing the upper part 20 and the lower part 12 to the container, and a second fastening means 38 is configured to secure the upper part 20 and the lower part 12 together and separate from the container. The lower part 12 includes anchor points 34 adapted to receive the second fastening means 38 so that when the security device 10 is secured to the container via the first fastening means the security device 10 is movable relative to the container. Each anchor point 34 includes a narrow part and a wide part, and each second fastening means is configured to pass through the wide part of the respective anchor point 34 into the narrow part of the respective anchor point for securing the upper part 20 to the lower part 12.
Patent NZ-624460-A (NZ)
Title: Process for making modulators of cystic fibrosis transmembrane conductance regulator
Inventor: KRUEGER BRIAN R
IPC: C07C211/45
Filed: 2010-03-19
Abstract: The disclosure provides a process for the preparation of a compound of Formula 8; comprising nitrating a compound of Formula 7; The compound of Formula 5 may further be prepared by reduction of 8. where R2 and R4 are each tert-butyl, and PG is a protecting group such as propoxy formyl, methanesulfonyl, 4-nitrobenzoyl, ethoxy formyl, butoxy formyl, t-butoxy formyl, i-propoxy formyl or methoxy formyl.
Patent NZ-629700-A (NZ)
Title: Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
Inventor: VESEY GRAHAM
IPC: C12N5/0775
Filed: 2013-12-24
Abstract: Disclosed is a method for producing a vaccine for the treatment or prevention of cancer, the vaccine comprising solubilized components of a cancer cell or cancer-associated cell, and a non-mammalian polypeptide selected from streptavidin, avidin or neutravidin or a fragment or variant thereof which is capable of binding a mammalian protein, the method comprising exposing a biological sample comprising at least one cancer cell or cancer- associated cell to an ionic detergent, a reducing agent, and a non-mammalian polypeptide capable of binding a mammalian protein, to produce a solubilized biological sample comprising components from the cancer cell or cancer-associated cell, and a non- mammalian polypeptide capable of binding a mammalian protein.
Patent NZ-630526-A (NZ)
Title: A refrigeration cassette and refrigerator unit
Inventor: ROBERT STEWART
IPC: F25D19/02
Filed: 2014-09-09
Abstract: A refrigeration cassette containing refrigeration components, typically including condenser, compressor and evaporator, can be installed top or bottom of a cabinet without altering orientation. This is typically achieved with knock out panels of cassette, and levering means to secure cassette sealed against either top or bottom to allow air in cabinet to flow through evaporator, and ambient air to flow over condenser and compressor.
Patent NZ-700990-A (NZ)
Title: Improvements to implant surfaces
Inventor: PETER JAMES BURN
IPC: A61F2/02
Filed: 2014-06-05
Abstract: A patient-specific acetabular implant 200 including a hemispherical cup portion and an acetabular rim surrounding the perimeter of the hemispherical cup formed at least partially using additive manufacturing, where the implant surface includes at least one area of integrally formed three dimensional scaffold and one area of rough, textured surface 220. The implant 200 further includes one or more regions of polished surface 240, with at least one region of polished surface 240 positioned on the acetabular rim.
Patent NZ-711229-A (NZ)
Title: Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as ssao inhibitors
Inventor: SAVORY EDWARD
IPC: C07D471/04
Filed: 2014-03-13
Abstract: The compounds of formula (I) are inhibitors of semicarbazide- sensitive amine oxidase (SSAO) activity useful in the treatment of inflammation, an inflammatory disease, an immune or an autoimmune disorder, or inhibition of tumour growth.
Patent NZ-711781-A (NZ)
Title: Trampolines and trampoline parks
Inventor: ANDON JOE
IPC: A63B5/11
Filed: 2015-07-10
Abstract: A trampoline or trampoline system including a frame or other foundation; biasing means mounted on or to said frame or other foundation; and a plurality of jumping mats connected to selected first ones of said biasing means respectively above said frame or other foundation in side by side relationship, said selected first ones of said biasing means being arranged to bias said plurality of mats outwards to tension said mats, and said plurality of mats being operatively connected to each other along respective adjacent portions thereof and/or to selected second ones of said biasing means along their respective adjacent portions, said second ones of said biasing means being arranged to bias adjacent ones of said plurality of mats upwards and/or outwards away from their respective centres and/or towards each other.
Patent NZ-717594-A (NZ)
Title: Oil-based adjuvants
Inventor: DOMINOWSKI PAUL JOSEPH
IPC: A61K39/39
Filed: 2014-09-19
Abstract: The instant invention provides various formulations comprising combinations of immunostimulating oligonucleotides, polycationic carriers, sterols, saponins, quaternary amines, TLR-3 agonists, glycolipids, and MPL-A or analogs thereof in oil emulsions, use thereof in preparations of immunogenic compositions and vaccines, and use thereof in the treatment of animals. More specifically, the present invention provides oil emulsions with at least 50 % (v/v) oily phase that may be used with antigens to form vaccine compositions.